RxDoctor Payments Data

Robert Wozniak, MD

Interventional Cardiology · Austin, TXNPI 1063408128

Payments from drug & device makers

$27,030in general payments, 2019–2025

Across 758 payments — averaging $35.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$4K
  • Shockwave Medical, Inc$3K
  • Boston Scientific$3K
  • Medtronic$3K
  • Amgen$2K
  • Abbott$1K
  • plus $11K from 54 others

What the payments were for

  • Travel & lodging$4,09116%
  • Food & beverage$22,17084%
  • Education$560%
  • Gifts$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abiomed62$3,743
Shockwave Medical, Inc32$3,304
Boston Scientific26$3,094
Medtronic(2 entities)35$2,655
Amgen83$1,624
Abbott31$1,259
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)56$1,052
Regeneron Healthcare Solutions, Inc.33$816
AstraZeneca41$789
Endologix LLC7$787
Johnson & Johnson(2 entities)53$739
Impulse Dynamics (USA) Inc.24$562
Chiesi USA, Inc.7$524
Novo Nordisk23$489
E.r. Squibb & Sons, L.L.C.28$454
Novartis24$441
Amryt Pharma Holdings Ltd6$417
Pfizer19$415
Boehringer Ingelheim19$380
Atricure, Inc.6$377
Merck13$256
Bolton Medical Inc8$211
Medicure Pharma Inc.2$210
Amarin Pharma, Inc.11$190
Penumbra, Inc.1$169
Sanofi-aventis U.S. LLC8$160
Actelion Pharmaceuticals US, Inc.16$137
Tactile Systems Technology Inc7$108
Lexicon Pharmaceuticals, Inc.3$104
Angiodynamics, Inc.2$98
Bayer4$86
Inspire Medical Systems, Inc.3$85
Heartflow, Inc.3$80
Teleflex LLC5$79
Terumo Medical Corporation3$78
Kowa Pharmaceuticals America, Inc.5$74
Esperion Therapeutics, Inc.4$73
Philips North America LLC2$73
Biosense Webster, Inc.2$71
Kiniksa Pharmaceuticals, Ltd.4$66
GSK3$66
Azurity Pharmaceuticals, Inc.3$61
Inari Medical, Inc.3$60
Acist Medical Systems, Inc.2$56
Althera Pharmaceuticals LLC3$53
Scpharmaceuticals Inc.3$43
Lantheus Medical Imaging, Inc.2$39
Bardy Diagnostics, Inc.2$34
Corcept Therapeutics2$33
Myocardial Solutions, Inc.1$33
Arbor Pharmaceuticals, Inc.2$33
Cardiva Medical, Inc.1$26
Flowphysix Inc1$25
Kiniksa Pharmaceuticals International, PLC1$22
Agepha Pharma FZ LLC1$20
W. L. Gore & Associates, Inc.1$20
Itamar Medical Inc1$19
Irhythm Technologies, Inc.1$16
Elutia, Inc.1$16
Medicomp Inc1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,030 in reported general payments places this provider in the 70th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$235,550
Medicare patients
1,144
Services billed
3,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban217$225,239
XareltoRivaroxaban95$122,963
Repatha SureclickEvolocumab137$100,219
EntrestoSacubitril/Valsartan75$89,901
Praluent PenAlirocumab52$30,494
JardianceEmpagliflozin22$22,655
BrilintaTicagrelor31$18,198
VascepaIcosapent Ethyl15$10,007
EdarbiAzilsartan Medoxomil16$9,594
MultaqDronedarone Hcl16$7,842
Icosapent Ethyl23$7,701
Rosuvastatin Calcium456$7,417
Ranolazine ErRanolazine51$6,858
Metoprolol Succinate294$4,549
Losartan Potassium349$3,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$415$225,239217 claims
Johnson & JohnsonXarelto$739$122,96395 claims
NovartisEntresto$441$89,90175 claims
Boehringer IngelheimJardiance$380$22,65522 claims
AstraZenecaBrilinta$789$18,19831 claims
Arbor Pharmaceuticals, Inc.Edarbi$33$9,59416 claims
Sanofi-aventis U.S. LLCMultaq$160$7,84216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →